U.S. Markets open in 1 hr 40 mins
  • S&P Futures

    3,749.50
    +59.25 (+1.61%)
     
  • Dow Futures

    29,921.00
    +383.00 (+1.30%)
     
  • Nasdaq Futures

    11,514.25
    +228.50 (+2.02%)
     
  • Russell 2000 Futures

    1,746.50
    +31.60 (+1.84%)
     
  • Crude Oil

    84.79
    +1.16 (+1.39%)
     
  • Gold

    1,713.50
    +11.50 (+0.68%)
     
  • Silver

    20.85
    +0.27 (+1.29%)
     
  • EUR/USD

    0.9892
    +0.0065 (+0.6628%)
     
  • 10-Yr Bond

    3.6510
    0.0000 (0.00%)
     
  • Vix

    29.23
    -2.39 (-7.56%)
     
  • GBP/USD

    1.1343
    +0.0024 (+0.2098%)
     
  • USD/JPY

    144.8100
    +0.1900 (+0.1314%)
     
  • BTC-USD

    19,936.52
    +715.50 (+3.72%)
     
  • CMC Crypto 200

    453.08
    +17.73 (+4.07%)
     
  • FTSE 100

    7,042.26
    +133.50 (+1.93%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

ATI Physical Therapy Reports Fourth Quarter and Full Year 2021 Results

·25 min read

Company Provides 2022 Earnings Guidance

BOLINGBROOK, Ill., Feb. 25, 2022 /PRNewswire/ -- ATI Physical Therapy – ("ATI" or the "Company") (NYSE: ATIP), the largest single-branded outpatient physical therapy provider in the United States, today reported financial results for the fourth quarter and full year ended December 31, 2021.

ATI Physical Therapy Logo
ATI Physical Therapy Logo

"We achieved our revenue guidance for the year and approximated the low end of our Adjusted EBITDA1 range," said Jack Larsen, Executive Chairman of ATI Physical Therapy. "Despite a pronounced impact from recent COVID variants on daily operations, disrupting both patient scheduling and clinical staff attendance, our nationwide team stayed true to our central mission to deliver high quality care and service to our customers as illustrated by an increase in our Net Promotor Score to 78 from 73 during the third quarter and a Google Star Rating of 4.8."

Mr. Larsen continued, "During the quarter, we also saw increased therapist retention, with annualized clinician turnover declining 400 basis points quarter over quarter, and clinical FTE increasing to nearly 2,500. Moreover, we refreshed our sales and marketing strategy and have identified high priority channels for our field-based sales team, working closely with our clinic directors, to drive referrals and visits throughout the year."

Joe Jordan, Chief Financial Officer of ATI Physical Therapy, added, "As discussed below, we refinanced our first lien term loan this week with a new credit agreement and revolving credit facility and issued perpetual preferred stock with detachable warrants. With this refinancing transaction, we reduced leverage and increased liquidity in order to establish a strong footing to support operations and invest in our people and growth strategies as we work to continue scaling the business."

Fourth Quarter 2021 Results

Supplemental tables of key performance metrics for the first quarter of 2019 through the fourth quarter of 2021 are presented after the financial statements at the end of this press release. Commentary on performance results in the fourth quarter of 2021 is as follows:

  • Net operating revenue was $155.8 million compared to $159.0 million in the third quarter of 2021 and $153.1 million in the fourth quarter of 2020, a decrease of 2.0% quarter over quarter and an increase of 1.7% year over year.

  • Visits per Day ("VPD") were 20,649 compared to 20,674 in the third quarter of 2021 and 19,441 in the fourth quarter of 2020, essentially flat quarter over quarter and an increase of 6.2% year over year.

    VPD per Clinic was 22.8 compared to 23.1 in the third quarter of 2021 and 22.2 in the fourth quarter of 2020, a decrease of 0.3 quarter over quarter and an increase of 0.6 year over year. During the last 2 weeks in December 2021, there was a significant negative impact to visits across our platform as the Omicron wave of COVID caused an increase in patient appointment cancellations, clinical staff sick absences, and overall decline in referral volume.

  • Rate per Visit was $104.51 compared to $105.56 in the third quarter of 2021 and $109.98 in the fourth quarter of 2020, a decrease of 1.0% quarter over quarter and 5.0% year over year. The decreases were primarily due to continued unfavorable incremental mix shifts in payor classes, states and services.

  • Salaries and related costs were $88.1 million compared to $86.8 million in the third quarter of 2021 and $79.1 million in the fourth quarter of 2020, an increase of 1.4% quarter over quarter and 11.3% year over year due to lower labor productivity and wage inflation.

    PT salaries and related costs per Visit were $55.73 compared to $53.70 in the third quarter of 2021 and $52.16 in the fourth quarter of 2020, an increase of 3.8% quarter over quarter and 6.9% year over year. The increases were due to lower labor productivity of 8.3 VPD per clinical FTE compared to 8.8 in both the third quarter of 2021 and the fourth quarter of 2020. The year over year increase was also due to wage inflation experienced in certain pockets of the country in 2021 compared to 2020.

  • Rent, clinic supplies, contract labor and other was $47.8 million compared to $45.8 million in the third quarter of 2021 and $42.8 million in the fourth quarter of 2020, an increase of 4.4% quarter over quarter and an increase of 11.6% year over year due to more clinics, higher use of contract labor, and higher advertising expenses.

    PT rent, clinic supplies, contract labor and other per Clinic was $50,976 compared to $49,499 in the third quarter of 2021 and $47,168 in the fourth quarter of 2020, an increase of 3.0% quarter over quarter and 8.1% year over year. The sequential quarter and year over year increases were primarily driven by greater use of contract labor while we worked to fill open positions. An additional contributor was higher advertising expenditures.

  • Provision for doubtful accounts was $2.1 million compared to $3.5 million in the third quarter of 2021 and $3.3 million in the fourth quarter of 2020. PT provision as a percent of net patient revenue was 1.5% compared to 2.5% in the third quarter of 2021 and 2.4% in the fourth quarter of 2020, reflecting improved collections.

  • Selling, general and administrative expenses were $29.9 million compared to $30.8 million in the third quarter of 2021 and $30.0 million in the fourth quarter of 2020, a decrease of 2.9% quarter over quarter and 0.5% year over year primarily due to variations in non-recurring expenditures.

  • Income tax benefit was $12.4 million compared to $28.3 million in the third quarter of 2021 and $2.0 million in the fourth quarter of 2020.

  • Net income (loss) was $8.7 million compared to $(333.8) million in the third quarter of 2021 and $2.2 million in the fourth quarter of 2020. The third quarter 2021 net loss included significant non-cash items, notably goodwill and intangible asset impairment charges of $(509.0) million and change in fair value of warrant liability and contingent common shares liability of $162.2 million. The non-cash change in fair value of warrant liability and contingent common shares liability in the fourth quarter of 2021 was $10.0 million.

  • Adjusted EBITDA1 was $1.6 million compared to $8.5 million in the third quarter of 2021 and $18.6 million (excluding CARES Act Provider Relief Funds of $24.1 million) in the fourth quarter of 2020, a decrease of 80.8% quarter over quarter and 91.2% year over year. The sequential quarter decrease was primarily driven by lower revenue and higher salaries and related costs and higher rent, clinic supplies, and contract labor costs.

    Adjusted EBITDA margin was 1.1% compared to 5.4% in the third quarter of 2021 and 12.2% (excluding CARES Act Provider Relief Funds) in the fourth quarter of 2020.

  • Net (decrease) increase in cash was $(17.5) million compared to $(24.5) million in the third quarter of 2021 and $11.9 million in the fourth quarter of 2020. Cash use in the fourth quarter of 2021 included $9.2 million in connection with the Medicare Accelerated and Advance Payment Program ("MAAPP") and deferral of the employer portion of Social Security taxes under the CARES Act.

Summary of key balance sheet items as of December 31, 2021 is as follows:

  • Cash and cash equivalents totaled $48.6 million, and the revolving credit facility was undrawn with available capacity of $19.8 million, net of usage by letters of credit, equaling $68.4 million in available liquidity.

Other notable achievements and/or news in the fourth quarter of 2021 were as follows:

  • Opened 20 new clinics in existing states, including Georgia, Massachusetts, Michigan, and Texas; and closed 10 clinics primarily in Illinois. This brings the total number of clinics for the year to 910. The company continues to capitalize on growth opportunities in individual markets, while optimizing its footprint and financial return in other local markets.

  • Net Promotor Score ("NPS") of 78 and Google Star Rating of 4.8, reflecting continued high customer satisfaction and brand loyalty.

Full Year 2021 Results

Commentary on performance results for the full year 2021 is as follows:

  • Net operating revenue was $627.9 million compared to $592.3 million for the full year 2020, an increase of 6.0% year over year.

  • Salaries and related costs were $336.5 million compared to $306.5 million for the full year 2020, an increase of 9.8% year over year.

  • Rent, clinic supplies, contract labor and other was $180.9 million compared to $166.1 million for the full year 2020, an increase of 8.9% year over year.

  • Provision for doubtful accounts was $16.4 million compared to $16.2 million for the full year 2020. Provision as a percent of net operating revenue was 2.6% compared to 2.7% for the full year 2020.

  • Selling, general and administrative expenses were $111.8 million compared to $104.3 million for the full year 2020, an increase of 7.2% year over year.

  • Non-cash goodwill and intangible asset impairment charges totaled $962.3 million. As a result of revisions to our forecasts reported in July and October 2021, including the factors related to our revisions of the forecasts, it was determined that the fair value amounts of goodwill and trade name were below their respective carrying amounts.

  • Income tax benefit was $71.0 million compared to an expense of $2.1 million for the full year 2020.

  • Net (loss) income was $(782.0) million compared to $(0.3) million for the full year 2020.

  • Adjusted EBITDA1 was $39.8 million compared to $63.6 million (excluding CARES Act Provider Relief Funds of $91.5 million) for the full year 2020, a decrease of 37.5% year over year.

    Adjusted EBITDA margin was 6.3% compared to 10.7% (excluding CARES Act Provider Relief Funds) for the full year 2020.

  • Net (decrease) increase in cash was approximately $(93.5) million compared to an increase of $103.8 million in cash for the full year 2020.

Refinancing and Equity Issuance

In February 2022, we entered into a new credit agreement for a $500 million term loan maturing in 2028 and executed a new $50 million revolving credit facility maturing in 2027. Additionally, we issued $165 million in Series A perpetual preferred stock accruing a dividend (payable in kind) at 12% per annum, subject to adjustments in certain circumstances, with approximately 11.5 million detachable warrants to purchase shares of our common stock. The warrants represent 5.5% of our common stock on a fully-diluted basis. Proceeds from the transaction were used to pay off the previously outstanding term loan of $555 million due in 2023, pay fees on the transaction, and add approximately $77 million to our balance sheet providing capital to support operations and accelerate growth. See our Form 8-K filed on February 25, 2022 for additional information.

2022 Guidance

For the full year 2022, ATI expects net operating revenue to be in a range of $675 million to $705 million, which represents approximately 7.5% to 12.3% year over year growth. We anticipate continuing to ramp visits steadily throughout 2022 as we continue to grow clinical headcount and execute on the sales and marketing strategy put in place at the end of 2021. We expect Adjusted EBITDA1 will ramp throughout 2022 as revenue ramps, however, we expect a higher expense ratio early in 2022 as we have made the decision to hire clinicians in advance of volume improvements anticipated from our sales and marketing strategy. Adjusted EBITDA for 2022 is expected to be in a range of $25 million to $35 million.

As we reignite prior referral relationships and set the groundwork to build long-term connections with new target referral providers, we expect to return to pre-COVID visit volumes by the end of 2022.

While we continue to ramp our existing clinics, we are also seeing incremental growth opportunities in select markets and accordingly expect to open approximately 35 new clinics in 2022.

Fourth Quarter and Year End 2021 Earnings Conference Call

Management will host a conference call at 8:00 a.m. Eastern Time on February 25, 2022 to review fourth quarter and full year 2021 financial results. The conference call can be accessed via a live audio webcast. To join, please access the following web link, Q4 2021 Year-End Earnings Conference Call, on the Company's Investor Relations website at https://investors.atipt.com at least 15 minutes early to register, and download and install any necessary audio software. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About ATI Physical Therapy

At ATI Physical Therapy, we are passionate about potential. Every day, we restore it in our patients and activate it in our team members in our more than 900 locations in 25 states. With outcomes from more than 2.5 million unique patient cases, ATI is making strides in the industry by setting quality standards that deliver predictable outcomes for our patients with musculoskeletal (MSK) issues. ATI's offerings span across a broad spectrum for MSK-related issues. From preventative services in the workplace and athletic training support to outpatient clinical services and online physical therapy via our online platform, CONNECT™, a complete list of our service offerings can be found at ATIpt.com. ATI is based in Bolingbrook, Illinois.

1 Refer to "Non-GAAP Financial Measures" below.

Forward-Looking Statements

All statements other than statements of historical facts contained in this communication are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions (or the negative versions of such words or expressions) that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding 2022 forecast and other estimates of financial and performance metrics and market opportunity. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of ATI's management and are not predictions of actual performance. These forward-looking statements are estimates only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of ATI. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to:

(i)

changes in domestic business, market, financial, political and legal conditions, including shifts and trends in payor mix;

(ii)

the ability to execute on our sales and marketing strategies;

(iii)

the ability to maintain the listing of the Company's securities on NYSE;

(iv)

the ability of the Company to realize the anticipated benefits of the business combination;

(v)

risks related to the rollout of ATI's business strategy, including but not limited to ramping of visits, growing clinical headcount, and opening new clinics, and the timing of expected business milestones;

(vi)

the effects of competition on ATI's future business and the ability of ATI to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees;

(vii)

the ability of the Company to retain and to hire physical therapists consistent with its business plan;

(viii)

the ability of the Company to develop new and retain and expand relationships with referral sources;

(ix)

the outcome of any legal proceedings or regulatory investigations that have or may be instituted against the Company or any of its directors or officers;

(x)

the ability of the company to comply with its covenants in its credit facility and preferred stock financing arrangements or to redeem preferred stock;

(xi)

the ability of the Company to issue equity or equity-linked securities or obtain debt financing in the future;

(xii)

risks related to political and macroeconomic uncertainty;

(xiii)

the impact of the global COVID-19 pandemic (and existing or emerging variants) on any of the foregoing risks;

(xiv)

risks related to the impact on our workforce of mandatory COVID-19 vaccination of employees; and

those factors discussed in our amended S-1 registration statement filed with the SEC on July 28, 2021 under the heading "Risk Factors," and our Form 10-K for the fiscal year ended December 31, 2021 and other documents filed, or to be filed, by ATI with the SEC.

If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements, including our forecast update. There may be additional risks that ATI does not presently know or that ATI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, the forward-looking statements in this communication reflect ATI's expectations, plans or forecasts of future events and views as of the date of this communication. ATI anticipates that subsequent events and developments will cause ATI's assessments with respect to these forward-looking statements to change. However, while ATI may elect to update these forward-looking statements at some point in the future, ATI specifically disclaims any obligation to publicly update any forward-looking statement, whether written or oral, which may be made from time to time, whether as a result of new information, future developments or otherwise, unless required by applicable law. These forward-looking statements should not be relied upon as representing ATI's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Non-GAAP Financial Measures

To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "Adjusted EBITDA" and "Adjusted EBITDA margin." We believe Adjusted EBITDA and Adjusted EBITDA margin (i.e. Adjusted EBITDA divided by Net Operating Revenue) assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or the ratio of net income (loss) to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of cash available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

Please see "Reconciliation of GAAP to Non-GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures. We are unable to provide a reconciliation between forward-looking Adjusted EBITDA to its comparable GAAP financial measure without unreasonable effort, due to the high difficulty and impracticability of predicting certain amounts required by GAAP with a reasonable degree of accuracy by the date of this release.

Contact:

Joanne Fong
SVP, Treasurer and Investor Relations
(630) 296-2222 x 7131
investors@atipt.com

ATI Physical Therapy

Condensed Consolidated Statements of Operations

($ in thousands)

(unaudited)



Three Months Ended


Year Ended



December 31, 2021


December 31, 2020


December 31, 2021


December 31, 2020











Net patient revenue

$

140,275



$

136,840



$

561,080



$ 529,585



Other revenue

15,488



16,266



66,791



62,668



Net operating revenue

155,763



153,106



627,871



592,253












Clinic operating costs:




Salaries and related costs

88,087



79,117



336,496



306,471




Rent, clinic supplies, contract labor and other

47,792



42,824



180,932



166,144



Provision for doubtful accounts

2,099



3,332



16,369



16,231



Total clinic operating costs

137,978



125,273



533,797



488,846



Selling, general and administrative expenses

29,897



30,032



111,809



104,320



Goodwill and intangible asset impairment charges





962,303





Operating loss

(12,112)



(2,199)



(980,038)



(913)



Change in fair value of warrant liability

(2,171)





(22,595)





Change in fair value of contingent common shares liability

(7,875)





(175,140)





Loss on settlement of redeemable preferred stock





14,037





Interest expense, net

7,215



16,404



46,320



69,291



Interest expense on redeemable preferred stock



5,154



10,087



19,031



Other (income) expense, net

(5,590)



(23,914)



241



(91,002)



(Loss) income before taxes

(3,691)



157



(852,988)



1,767



Income tax (benefit) expense

(12,427)



(2,033)



(70,960)



2,065



Net income (loss)

8,736



2,190



(782,028)



(298)





















ATI Physical Therapy

Condensed Consolidated Balance Sheets

($ in thousands)

(unaudited)



December 31, 2021


December 31, 2020

Assets:




Current assets:




Cash and cash equivalents

$ 48,616


$ 142,128

Accounts receivable (net of allowance for doubtful accounts of $53,533 and
$69,693 at December 31, 2021 and December 31, 2020, respectively)

82,455


90,707

Prepaid expenses

9,303


3,859

Other current assets

3,204


2,168

Total current assets

143,578


238,862





Non-current assets:




Property and equipment, net

139,730


137,174

Operating lease right-of-use assets

256,646


258,227

Goodwill, net

608,811


1,330,085

Trade name and other intangible assets, net

411,696


644,339

Other non-current assets

2,233


1,685

Total assets

$ 1,562,694


$ 2,610,372





Liabilities and Stockholders' Equity:




Current liabilities:




Accounts payable

$ 15,146


$ 12,148

Accrued expenses and other liabilities

64,584


70,690

Current portion of operating lease liabilities

49,433


52,395

Current portion of long-term debt

8,167


8,167

Total current liabilities

137,330


143,400





Long-term debt, net

543,799


991,418

Redeemable preferred stock


163,329

Warrant liability

4,341


Contingent common shares liability

45,360


Deferred income tax liabilities

67,459


138,547

Operating lease liabilities

250,597


253,990

Other non-current liabilities

2,301


18,571

Total liabilities

1,051,187


1,709,255





Commitments and contingencies








Stockholders' equity:




Preferred stock, $0.0001 par value; 1.0 million shares authorized; none issued
and outstanding at December 31, 2021 and December 31, 2020


Class A common stock, $0.0001 par value; 470.0 million shares authorized;
207.4 million shares issued, 197.4 million shares outstanding at December 31,
2021; 138.9 million shares issued, 128.3 million shares outstanding at
December 31, 2020

20


13

Treasury stock, at cost, 0.03 million shares and none at December 31, 2021 and
2020, respectively

(95)


Additional paid-in capital

1,351,597


954,728

Accumulated other comprehensive income (loss)

28


(1,907)

Accumulated deficit

(847,132)


(68,804)

Total ATI Physical Therapy, Inc. equity

504,418


884,030

Non-controlling interests

7,089


17,087

Total stockholders' equity

511,507


901,117

Total liabilities and stockholders' equity

$ 1,562,694


$ 2,610,372

ATI Physical Therapy

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(unaudited)



Year Ended


December 31, 2021


December 31, 2020

Operating activities:




Net loss

$ (782,028)


$ (298)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:




Goodwill and intangible asset impairment charges

962,303


Depreciation and amortization

37,995


39,700

Provision for doubtful accounts

16,369


16,231

Deferred income tax provision

(71,088)


1,814

Amortization of right-of-use assets

45,536


44,526

Share-based compensation

5,754


1,936

Amortization of debt issuance costs and original issue discount

3,252


4,109

Non-cash interest expense


6,335

Non-cash interest expense on redeemable preferred stock

10,087


19,031

Loss on extinguishment of debt

5,534


Loss on settlement of redeemable preferred stock

14,037


(Gain) loss on disposal and impairment of assets

(5,189)


469

Loss on lease terminations and impairment


3,863

Change in fair value of warrant liability

(22,595)


Change in fair value of contingent common shares liability

(175,140)


Changes in:




Accounts receivable, net

(10,201)


(3,307)

Prepaid expenses and other current assets

(6,688)


4,841

Other non-current assets

(284)


413

Accounts payable

1,831


798

Accrued expenses and other liabilities

(5,288)


9,174

Operating lease liabilities

(50,942)


(42,819)

Other non-current liabilities

861


5,056

Medicare Accelerated and Advance Payment Program Funds

(12,605)


26,732

Transaction-related amount due to former owners

(3,611)


Net cash (used in) provided by operating activities

(42,100)


138,604





Investing activities:




Purchases of property and equipment

(40,293)


(21,887)

Purchases of intangible assets

(1,675)


(250)

Proceeds from sale of property and equipment

223


328

Proceeds from sale of clinics

248


Proceeds from sale of Home Health service line

6,131


Business acquisitions, net of cash acquired

(4,523)


Net cash used in investing activities

(39,889)


(21,809)





Financing activities:




Deferred financing costs


(350)

Principal payments on long-term debt

(456,202)


(8,167)

Proceeds from revolving line of credit


68,750

Payments on revolving line of credit


(68,750)

Cash inflow from Business Combination

229,338


Payments to Series A Preferred stockholders

(59,000)


Proceeds from shares issued through PIPE investment

300,000


Payments for equity issuance costs

(19,233)


Taxes paid on behalf of employees for shares withheld

(128)


Distribution to non-controlling interest holder

(6,298)


(4,453)

Net cash used in financing activities

(11,523)


(12,970)





Changes in cash and cash equivalents:




Net (decrease) increase in cash and cash equivalents

(93,512)


103,825

Cash and cash equivalents at beginning of period

142,128


38,303

Cash and cash equivalents at end of period

$ 48,616


$ 142,128





Supplemental noncash disclosures:




Derivative changes in fair value

$ (1,935)


$ 582

Purchases of property and equipment in accounts payable

$ 4,177


$ 3,010

Warrant liability recognized upon the closing of the Business Combination

$ (26,936)


$ —

Contingent common shares liability recognized upon the closing of the Business
Combination

$ (220,500)


$ —

Shares issued to Wilco Holdco Series A Preferred stockholders

$ 128,453


$ —





Other supplemental disclosures:




Cash paid for interest

$ 41,937


$ 58,421

Cash paid for (received from) taxes

$ 81


$ (1,098)

ATI Physical Therapy

Supplemental Tables of Key Performance Metrics




Financial Metrics ($ in 000's)



Net Patient Revenue

Other

Revenue

Net Operating Revenue

Adjusted EBITDA(1)

Adj EBITDA margin(1)

Q1 2019


$170,940

$16,277

$187,217

$25,989

13.9%

Q2 2019


$182,757

$16,015

$198,772

$33,342

16.8%

Q3 2019


$179,561

$16,624

$196,185

$29,455

15.0%

Q4 2019


$184,338

$18,946

$203,284

$39,606

19.5%

Q1 2020


$164,939

$17,799

$182,738

$26,487

14.5%

Q2 2020


$95,003

$12,751

$107,754

$1,189

1.1%

Q3 2020


$132,803

$15,852

$148,655

$17,321

11.7%

Q4 2020


$136,840

$16,266

$153,106

$18,622

12.2%

Q1 2021


$132,271

$16,791

$149,062

$5,590

3.8%

Q2 2021


$146,679

$17,354

$164,033

$23,999

14.6%

Q3 2021


$141,855

$17,158

$159,013

$8,539

5.4%

...

Q4 2021


$140,275

$15,488

$155,763

$1,643

1.1%










(1)

Excludes CARES Act Provider Relief Funds of $44.3 million in the second quarter of 2020, $23.1 million in the third quarter of 2020, and $24.1 million in the fourth quarter of 2020.




Operational Metrics: PT Clinics